Review Article
Review on Medical Applications of Manganese Oxide (Mn2+, Mn3+, and Mn4+) Magnetic Nanoparticles
Table 3
Manganese oxides-based drug delivery carrier.
| S. no. | Nanoformulation | Preparation method | Size (nm) | PDI (mV) | Zeta potential (mV) | Drug | Drug-loading efficiency (%) | Drug encapsulation efficiency (%) | Drug release (%) | Disease | References |
| 1 | Polydopamine–manganese dioxide-IR780 iodide | Self-polymerization | 244.6 | 0.172 | −19.5 ± 1 | Polydopamine | 97.5 | 9.18 | — | — | [155] | 2 | Hollow MnO2 | Reduction | — | — | — | Doxorubicin | 20.0 | 50.2 | 38.7 | HeLa, MCF-7 | [178] | 3 | MnO2-DOX-C6 | Reduction | 55.34 ± 2.93 | 0.212 | 27.30 ± 2.11 | Doxorubicin | — | — | 66.84 ± 3.8 | — | [179] | 4 | DOX/MnO2@ZIF-8c | — | 206.22 ± 21.00 nm | — | — | Doxorubicin | 12 | — | 82 | Lung cancer | [181] | 5 | Biotin–PEG Mn3O4 nanocuboids | — | — | — | — | Gemcitabine | — | — | — | Breast cancer | [184] | 6 | Mno2 dopped triple hybrid mesoporous organosilica nanoparticles | Sol–gel method | 271 | — | −6.98 | Doxorubicin | — | 13.5 | — | Breast cancer | [187] | 7 | DUCNP@Mn−MOF/FOE | — | — | — | — | 3-F-10-OH-Evodiamine | 83 | — | — | — | [188] | 8 | ST-SA@MNCsb | Chemical precipitation | 21 nm | — | −15 | Doxorubicin hydrochloride | — | — | 81.4 ± 1.6 | HePG2 | [109] | 9 | DOX@(hPDA/MnO2)-PEG | — | 23.6 | — | −22.6 | Doxorubicin | — | — | 43 | — | [190] | 10 | Hollow MnO2 | — | 100 | — | −22 | Doxorubicin | 94.67 | — | — | — | [191] | 11 | tLyP-1-CD-DOPA-MnO2@PTXa | 137.0 ± 1.9 | — | 16.0 ± 1.3 | — | Paclitaxel | — | — | — | Orthotopic glioma | [192] | 12 | Aptamer mediated hollow MnO2 | 100 ± 10 | — | 33.84–36.06 | — | Sorafenib | 22 | 88 | 18 | Liver cancer | [193] | 13 | Mn3O4@PAA@ZIF-8/MTX | Hydrothermal | — | — | — | Methotrexate | 80 | — | 53 | BT-474 and MCF-7 | [194] | 14 | AuNPs@MnCO3/Mn3O4 | — | — | — | — | Doxorubicin and propium iodide | — | — | — | Breast cancer | [195] | 15 | Hollow MnO2 | — | 129 nm | — | −27 | Bufalin | 28.6 ± 3.5 | 80.0 ± 4.3 | 81 ± 2 | H22 | [196] | 16 | Au/MnO2 | — | 146 nm | — | +13.6 | Doxorubicin | 99.1 | — | 25 | — | [197] |
|
|
atLyP-1-CD-DOPA-MnO2@PTX, tLyP-1-modified dopamine (DOPA), β-cyclodextrin (CD)-coated paclitaxel (PTX), and manganese dioxide (MnO2)-loaded nanoparticles. bST-SA@MNCs—serotonin–stearic acid-based bioconjugate modified manganese oxide-based nanocuboids. cDOX/MnO2@ZIF-8—doxorubicin-loaded MnO2@Zeolitic Imidazolate Framework-8.
|